Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mol Cancer Res. 2017 Sep 28;16(1):58–68. doi: 10.1158/1541-7786.MCR-17-0408

Figure 7. Hsp70 Limits RIP1/3 Oligomerization.

Figure 7

(A) JG-98 toxicity does not depend on TNF signaling. MDA-MB-231 cells were pre-treated with Enbrel (5 μg/mL) for 1 hour prior to addition of compounds. Viability was determined by MTT assay. Results are the average of three independent experiments performed in quintuplicate. Error is SEM. **p value < 0.01 (B) JG-98 does not induce formation of a RIP1-caspase-8 complex. MDA-MB-231 cells were treated for 24 hours with indicated compounds. SM-164 was used at 100 nM. (C) Treatment with JG-98 (10 μM) favored formation of a high molecular mass oligomer of RIP1 and a reduction of RIP3. Co-treatment with z-VAD-fmk exacerbated this effect. Necrostatin could block the effects of JG-98. Results are representative of experiments performed in triplicate. (D) Treatment with 17-DMAG or bortezomib (BTZ) did not change RIP1 oligomerization.